Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization
Open Access
- 8 October 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0057024
Abstract
We observed an increase in the frequency of Candida auris among invasive candidiasis isolates in the 2022 SENTRY Antifungal Surveillance Program compared to prior years: ≤0.1% before 2018, 0.4%–0.6% from 2018 to 2021, and 1.6% in 2022. C. auris isolates were collected in seven countries, but 28 (35.9%) isolates were recovered in the USA (five states; more common in New York, Texas, and New Jersey) and 26 (33.3%) in Panama. Greece and Turkey had 12 and 9 isolates, respectively. Overall, 82.1% of the isolates were resistant to fluconazole; 17.9% were resistant to amphotericin B; and 1.3% were resistant to caspofungin, anidulafungin, or micafungin (Centers for Disease Control and Prevention tentative resistance breakpoints). Rezafungin inhibited 96.2% of the isolates (Clinical and Laboratory Standards Institute susceptibility breakpoint). Pandrug resistance was not observed, but 17.9% of the isolates were resistant to fluconazole and amphotericin B. South Asian (Clade I) isolates were most common ( n = 40, 51.3%); of these, 97.5% were resistant to fluconazole and 30.0% were resistant to amphotericin B. Thirty (38.5%) isolates belonged to the South American region (Clade IV), and 56.7% of those were resistant to fluconazole and 6.7% to amphotericin B. Seven isolates belonged to the South African Clade III and one to East Asian Clade II. Erg11 (Y132F, K143R, and F126L) and MRR1 (N647T) alterations were detected. One isolate that was resistant to all echinocandins carried an FKS R1354G alteration. Two isolates displayed elevated rezafungin minimum inhibitory concentration (MIC) values but low MIC values against other echinocandins and no FKS alterations. As C. auris is spreading globally, monitoring this species is prudent.Keywords
Funding Information
- Melinta Therapeutics
This publication has 34 references indexed in Scilit:
- Confirmation of fifth Candida auris clade by whole genome sequencingEmerging Microbes & Infections, 2022
- The molecular and genetic basis of antifungal resistance in the emerging fungal pathogen Candida aurisCurrent Opinion in Microbiology, 2022
- Global epidemiology of emerging Candida aurisCurrent Opinion in Microbiology, 2019
- Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse modelJournal of Antimicrobial Chemotherapy, 2018
- Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida aurisDiagnostic Microbiology and Infectious Disease, 2018
- Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogenMicrobiologyopen, 2018
- Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission ofCandida aurisand OtherCandidaSpeciesInfection Control & Hospital Epidemiology, 2017
- Simultaneous Emergence of Multidrug-ResistantCandida aurison 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological AnalysesClinical Infectious Diseases, 2016
- Whole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variationNew Microbes and New Infections, 2016
- Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance ProgrammeMycopathologia, 2012